Oncode is the independent institute dedicated to outsmarting cancer and impacting lives.
Carl Figdor and Michiel Vermeulen participate in the Oncode Institute for Radboudumc and Radboud University, respectively.
Research programmeDespite enormous progress in our understanding of cancer, the chance of long-term survival remains small for many patients, particularly those with metastatic disease. Oncode will address this unmet clinical need through an innovative basic research programme. True innovation in the treatment of cancer relies on new insights into the basic mechanisms of oncogenesis, which in turn depend heavily on technological innovation. Oncode research will be guided by a number of key questions that need to be resolved to extend life expectancy and improve quality of life for cancer patients.
Principal scientific questionsThe key issues in cancer research today are summed up in our principal scientific questions:
- Can we define new and better targets for therapy on the basis of detailed analyses of tumours, tumour-derived cell lines and organoids, and xenografts?
- What is the basis for tumour heterogeneity, and how can we harness this knowledge to refine cancer therapy?
- What role does the cell of origin play in a tumour’s characteristics and responsiveness to therapy?
- How do cancer cells avoid host immune attack, and how can we stop them from doing so?
- How do non-mutated background genes influence tumour formation and response to therapy?
- Can we develop novel models to predict therapy response?
- How can we prevent metastatic disease?
Scientific themesOn the basis of these questions, Oncode’s founding scientists have identified six scientific themes that constitute the basis of the integrated research strategy:
- Development of novel technologies
- Understanding the critical drivers of tumour growth and the causes of resistance
- Analysis of network perturbations in tumours and tumour-host interactions
- Causes and consequences of genetic instability
- Identification of critical drug combinations and biomarkers for personalized cancer treatments
- Mobilizing immune defence
Read more on the Oncode website.
Related news items
Social media posts on medication use during pregnancy often incorrect23 August 2019
Dutch social media regularly post about the safety of medicines for pregnant women. Many pregnant women use these posts as a source of information. A new analysis shows, however, that information found on social media about the risk of medication use often does not correspond with guidelines.read more
Hans van Bokhoven newly elected in Academia Europaea22 August 2019
The Academia Europaea is a functioning European Academy of Humanities, Letters and Sciences, composed of individual members.read more
Drug-induced interstitial lung disease in advanced breast cancer patients receiving everolimus22 August 2019
In Targeted Oncology, Annelieke Willemsen, Carla van Herpen and colleagues, showed that pulmonary function test with diffusion capacity of the lungs for carbon monoxide and serum biomarkers can be of aid to differentiate everolimus-related interstitial lung disease from other respiratory problems.read more
Publication in PNAS on dissecting EEC syndrome using single-cell RNA-seq22 August 2019
PhD candidates Eduardo Soares and Quan Xu in Jo Huiqing Zhou’s group in Molecular Developmental Biology, theme Reconstruction and regenerative medicine, have published a paper in PNAS on the disease mechanism of EEC syndrome using single-cell RNA-seq technology and patient-derived iPSCs.read more
Patient trust and participation in cell biological research21 August 2019
Alessandra Cambi and Gert Olthuis, discuss key ethical issues inherent in the development and the value of building trust and trustworthiness.read more
NWO grant for a tissue-generating patch to close diaphragmatic defects21 August 2019
Willeke Daamen and Toin van Kuppevelt, theme Reconstructive and regenerative medicine, were recently awarded a 690 k€ grant by NWO, domain Applied & Engineering Sciences, for the development of advanced patches for closure of diaphragmatic defects in children with congenital diaphragmatic hernia.read more